Education
About Us
Working with TipRanks
Follow Us
Cellectis SA (FR:ALCLS)
:ALCLS
ALCLS Stock Chart & Stats
Day’s Range― - ―
52-Week Range€1.01 - €2.55
Previous CloseN/A
Volume10.86K
Average Volume (3M)96.09K
Market Cap
$102.08M
Enterprise ValueN/A
Total Cash (Recent Filing)$260.31M
Total Debt (Recent Filing)$91.46M
Price to Earnings (P/E)―
Beta2.45
Next Earnings
Jul 31, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding72,093,636
10 Day Avg. Volume81,015
30 Day Avg. Volume96,090
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.90
Price to Sales (P/S)0.00
P/FCF Ratio5.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cellectis SA News
PremiumCompany Announcements
Cellectis SA Reports Q1 2025 Financial Results
PremiumPre-Earnings
Is CMVLF a Buy, Before Earnings?
PremiumCompany Announcements
Cellectis Reports 2024 Financial Results and Strategic Progress
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.07%
Mutual Funds
0.02% Other Institutional Investors
98.91% Public Companies and
Individual Investors
ALCLS FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was €1.01 and its highest was €2.55 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is $102.08M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Jul 31, 2025 which is in 64 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on May 12, 2025. The company reported -€0.161 earnings per share for the quarter, missing the consensus estimate of -€0.142 by -€0.019.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.18.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,093,636 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -€0.161 in its last earnings report, missing expectations of -€0.142. Following the earnings report the stock price went down -1.333%.
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in FR:ALCLS
Company Description
Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
ALCLS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, highlighting strategic collaboration, financial stability, and progress in clinical programs. However, challenges in ongoing arbitration and regulatory uncertainties were noted, but they did not overshadow the advancements and strategic gains made by the company.Read More>